Assistant Professor Eiichi Kodama of Tohoku University Hospital developed an anti-HIV drug (Elvitegravir : HIV integrase inhibitor) with Japan Tobaco Inc. during his tenure at Kyoto University. The combination tablet Stribild, which includes Elvitegravir, has approved by the U.S. Food and Drug Administration (the application for its approval was filed by Gilead Sciences, Inc).

More information (Japanese)

[Contact]

Assistant Professor Eiichi Kodama

Division of Infectious Diseases, Internal Medicine,

Tohoku University Hospital

TEL: +81-22-717-7199

E-mail: kodama515*med.tohoku.ac.jp (Replace * with @)

(Public Relations)

Associate Professor Fuji Nagami

Public Relations Office of Tohoku University Graduate School of Medicine

TEL: +81-22-717-7908

FAX: +81-22-717-8187

E-mail: f-nagami*med.tohoku.ac.jp (Replace * with @)